Question 16973 — pharmacy and medications

Summary

Mr. Bertrand Bouyx draws the attention of the Minister of Health, Families, Autonomy and Disabled People to the future of the system for early access to innovative medicines. The report recently published by the High Authority for Health highlights the major role played by this system since its creation, by allowing nearly 140,000 patients to benefit, before their authorization of access to the common law market, from treatments responding to insufficiently covered medical needs. This mechanism constitutes an important lever for people suffering from serious, rare or life-threatening diseases, for whom rapid access to therapeutic innovation can represent a decisive issue. However, several recent analyses, notably the European WAIT indicator, seem to show an increase in delays in accessing medicines. innovative in France compared to several European States. This development raises questions about the system's capacity to maintain rapid access to therapeutic innovations for the benefit of patients. During the examination of the social security financing bill for 2026, a reform of the early access system was considered before being withdrawn during the debates. On this occasion, the Government had indicated that consultation would be initiated with the various stakeholders in order to assess developments likely to guarantee the sustainability and effectiveness of the system. In this context, he would like to know if these consultations have been initiated and to know the directions that the Government is considering in order to preserve the effectiveness of the early access mechanism and to guarantee patients rapid access to innovations. therapeutic when their state of health justifies it, while ensuring the readability and sustainability of this system.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.